Back to Browse Journals » Research and Reports in Tropical Medicine » Volume 3

Implications of public-health insecticide resistance and replacement costs for malaria control: challenges and policy options for endemic countries and donors

Authors Miller MW, Tren R

Published Date April 2012 Volume 2012:3 Pages 1—19

DOI http://dx.doi.org/10.2147/RRTM.S30914

Received 16 February 2012, Accepted 24 February 2012, Published 24 April 2012

Michael W Miller1, Richard Tren2
1Duke Global Health Institute, Duke University, Durham, NC, USA; 2Africa Fighting Malaria, Washington, DC, USA

Abstract: Millions of people rely on public-health insecticides for malaria prevention. Yet growing insecticide resistance may threaten malaria control programs through decreasing effectiveness and possibly unsustainable cost-increases. Insufficient investment by stakeholders in the search for new public-health insecticides in recent decades has left malaria control programs with limited alternatives with which to manage resistance and maintain program effectiveness. While alternative insecticides are available, short of an unforeseen, significant increase in funding, their higher cost would compel programs to reduce malaria control coverage, leading to increased mortality and morbidity. In order to limit these negative effects on cost and coverage, we propose that policymakers and malaria stakeholders consider adoption of existing policies from successful efforts to secure reduced prices and increased access to other essential health interventions.

Keywords: vector control, indoor residual spraying (IRS), malaria control policy, research and development (R+D), priority review voucher (PRV), compulsory license

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

International advocacy against DDT and other public health insecticides for malaria control

Donald R Roberts, Richard Tren

Research and Reports in Tropical Medicine 2011, 2:23-30

Published Date: 20 January 2011

Readers of this article also read:

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Corrigendum

Brief G, Lammich T, Nagel E, Pfennigsdorf S, Spraul CW, Ho S

Clinical Ophthalmology 2012, 6:1271-1272

Published Date: 6 August 2012

Erratum

Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap

Page RL 2nd, Ghushchyan V, Allen RR, Roper L, Beck D, Johnathan BH, Frech-Tamas F, Chan W, McQueen RB, Nair KV

Drug, Healthcare and Patient Safety 2012, 4:67-74

Published Date: 10 July 2012

Smoking cessation: an economic analysis and review of varenicline

Michele A Faulkner

ClinicoEconomics and Outcomes Research 2009, 1:25-34

Published Date: 24 June 2009

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations

Akira Fujii, Norio Yasui-Furukori, Taku Nakagami, Takenori Niioka, Manabu Saito, et al

Drug Design, Development and Therapy 2008, 2:139-144

Published Date: 11 August 2008